Published in Invest Ophthalmol Vis Sci on June 28, 2011
Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol (2015) 1.05
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol (2011) 1.00
Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg. Case Rep Ophthalmol (2012) 1.00
Sustained-release corticosteroid options. J Ophthalmol (2014) 0.99
Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther (2014) 0.87
Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp Eye Res (2014) 0.83
Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema. Saudi J Ophthalmol (2014) 0.80
Short-term Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized Eyes with Recalcitrant Diabetic Macular Edema and Prior Anti-VEGF Therapy. J Ophthalmic Vis Res (2016) 0.79
Effect of dexamethasone intravitreal implant in a corneal graft rejection. Int J Ophthalmol (2016) 0.79
Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond) (2015) 0.79
Inflammation and macular oedema after pars plana vitrectomy. Mediators Inflamm (2013) 0.78
Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric patient with bilateral granulomatous idiopathic panuveitis: a case report. J Ophthalmic Inflamm Infect (2013) 0.77
Modified titanium implant as a gateway to the human body: the implant mediated drug delivery system. Biomed Res Int (2014) 0.77
INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations. Retina (2015) 0.77
Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes. Eye (Lond) (2016) 0.77
Clinical utility of intravitreal fluocinolone acetonide (Iluvien(®)) implant in the management of patients with chronic diabetic macular edema: a review of the current literature. Clin Ophthalmol (2017) 0.75
OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT. Retina (2016) 0.75
COMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT. Retina (2016) 0.75
Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes (2015) 0.75
[Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy]. Ophthalmologe (2016) 0.75
[Pharmacokinetics of systemic, regional and topical drugs for therapy of intraocular inflammation]. Ophthalmologe (2014) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology (2011) 4.61
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol (2003) 4.52
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (2011) 3.04
A general strategy for nanocrystal synthesis. Nature (2005) 2.90
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol (2007) 2.53
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci (2002) 2.19
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol (2006) 2.10
INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY. Retina (2016) 1.92
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol (2010) 1.82
Imaging pulsatile retinal blood flow in human eye. J Biomed Opt (2008) 1.73
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol (2002) 1.70
Monodisperse magnetic single-crystal ferrite microspheres. Angew Chem Int Ed Engl (2005) 1.69
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol (2009) 1.64
Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina (2010) 1.56
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52
Fluorescence resonant energy transfer biosensor based on upconversion-luminescent nanoparticles. Angew Chem Int Ed Engl (2005) 1.50
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology (2003) 1.48
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol (2011) 1.46
LAP-BAND for lower BMI: 2-year results from the multicenter pivotal study. Obesity (Silver Spring) (2013) 1.46
Sutureless 23-gauge versus 20-gauge vitrectomy with silicone oil injection in rhegmatogenous retinal detachment. Retina (2012) 1.46
Lanthanide-doped nanocrystals: synthesis, optical-magnetic properties, and applications. Acc Chem Res (2011) 1.42
Nucleation and growth of BaFxCl2-x nanorods. Chemistry (2008) 1.38
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology (2012) 1.32
Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol (2007) 1.26
Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina (2006) 1.25
Selective synthesis of Co3O4 nanocrystal with different shape and crystal plane effect on catalytic property for methane combustion. J Am Chem Soc (2008) 1.22
Single-molecule force spectroscopy reveals a mechanically stable protein fold and the rational tuning of its mechanical stability. Proc Natl Acad Sci U S A (2007) 1.22
Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology (2005) 1.22
Biodegradable implants for sustained drug release in the eye. Pharm Res (2010) 1.20
Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res (2007) 1.17
Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci (2004) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci (2006) 1.17
Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci (2006) 1.16
Cytokine and chemokine levels in tears from healthy subjects. Acta Ophthalmol (2010) 1.14
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol (2009) 1.13
Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci (2009) 1.13
Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology (2004) 1.13
Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol (2004) 1.11
Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. Stroke (2012) 1.10
Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 1.08
Ranibizumab. Nat Rev Drug Discov (2006) 1.08
Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina (2009) 1.07
Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells. Invest Ophthalmol Vis Sci (2005) 1.07
Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology (2004) 1.07
Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 1.06
Wet age-related macular degeneration. Adv Drug Deliv Rev (2005) 1.06
Au-ZnO hybrid nanopyramids and their photocatalytic properties. J Am Chem Soc (2011) 1.05
Uncertain compassion in using a drug before the risks and benefits are known. Arch Ophthalmol (2006) 1.05
Sarcoidosis in chronic granulomatous disease. Pediatrics (2006) 1.04
Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina (2014) 1.04
Controlled synthesis of semiconductor nanostructures in the liquid phase. Chem Soc Rev (2011) 1.04
Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000). Am J Ophthalmol (2008) 1.02
Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci (2007) 1.02
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Synthesis and characterization of bismuth single-crystalline nanowires and nanospheres. Inorg Chem (2004) 1.00
Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol (2011) 0.99
A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci (2006) 0.98
Upconversion luminescence of monodisperse CaF2:Yb(3+)/Er(3+) nanocrystals. J Am Chem Soc (2009) 0.98
A versatile bottom-up assembly approach to colloidal spheres from nanocrystals. Angew Chem Int Ed Engl (2007) 0.97
Atomic layer deposition and abrupt wetting transitions on nonwoven polypropylene and woven cotton fabrics. Langmuir (2010) 0.97
Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina (2013) 0.97
Hydrothermal synthesis of rare-earth fluoride nanocrystals. Inorg Chem (2006) 0.97
Interface-mediated growth of monodispersed nanostructures. Acc Chem Res (2007) 0.97
Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration. PLoS One (2013) 0.96
An effective oxidation route to blue emission CdSe quantum dots. Inorg Chem (2008) 0.96
Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol (2012) 0.96
Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. AIDS (2004) 0.96
Wurtzite Cu2ZnSnS4 nanocrystals: a novel quaternary semiconductor. Chem Commun (Camb) (2011) 0.95
Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol (2010) 0.95
Magnetic tuning of upconversion luminescence in lanthanide-doped bifunctional nanocrystals. Angew Chem Int Ed Engl (2013) 0.95